Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERVEBO Booster for Pre-Exposure Prophylaxis in Individuals at Occupational Risk for Ebola
NCT05959421Phase 3Withdrawn
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Ebola Zaire vaccine (live, attenuated) in Ebola virus disease (EVD) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoints: Course of Anti-EBOV immunoglobulin following primary vaccination, Anti-EBOV immunoglobulin at 12 months follow-up and 1 more. Planned start Jun 2026; status: withdrawn.
02
Drugs
Ebola Zaire vaccine (live, attenuated)
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT05959421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05959421.